Coherus Awaits August 2022 Date As FDA Accepts Ranibizumab Biosimilar
Company Set For Showdown With Samsung Bioepis For Biosimilar Lucentis
The US FDA has accepted for review the CHS-201 Lucentis biosimilar product developed by Formycon/Bioeq that is to be sold in the US by Coherus BioSciences, shortly after approving the first ranibizumab biosimilar to treat wet age-related macular degeneration.
